NO20065730L - Nye CIS-Imidazoliner - Google Patents
Nye CIS-ImidazolinerInfo
- Publication number
- NO20065730L NO20065730L NO20065730A NO20065730A NO20065730L NO 20065730 L NO20065730 L NO 20065730L NO 20065730 A NO20065730 A NO 20065730A NO 20065730 A NO20065730 A NO 20065730A NO 20065730 L NO20065730 L NO 20065730L
- Authority
- NO
- Norway
- Prior art keywords
- imidazolines
- new cis
- cis
- new
- antiproiferative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57227504P | 2004-05-18 | 2004-05-18 | |
| US61553404P | 2004-10-01 | 2004-10-01 | |
| US66877205P | 2005-04-06 | 2005-04-06 | |
| PCT/EP2005/005046 WO2005110996A1 (en) | 2004-05-18 | 2005-05-10 | Novel cis-imidazolines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20065730L true NO20065730L (no) | 2007-01-19 |
Family
ID=35058746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20065730A NO20065730L (no) | 2004-05-18 | 2006-12-12 | Nye CIS-Imidazoliner |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7964724B2 (ko) |
| EP (1) | EP1753727B1 (ko) |
| JP (1) | JP4814228B2 (ko) |
| KR (3) | KR20080027969A (ko) |
| CN (1) | CN1953965B (ko) |
| AR (1) | AR049545A1 (ko) |
| AT (1) | ATE414693T1 (ko) |
| AU (1) | AU2005243465B2 (ko) |
| BR (1) | BRPI0511328A (ko) |
| CA (1) | CA2565189A1 (ko) |
| DE (1) | DE602005011132D1 (ko) |
| ES (1) | ES2314660T3 (ko) |
| IL (1) | IL178884A (ko) |
| MX (1) | MXPA06013246A (ko) |
| MY (1) | MY143800A (ko) |
| NO (1) | NO20065730L (ko) |
| PE (1) | PE20060679A1 (ko) |
| RU (1) | RU2006144811A (ko) |
| TW (1) | TW200600501A (ko) |
| WO (1) | WO2005110996A1 (ko) |
| ZA (1) | ZA200609595B (ko) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7893278B2 (en) * | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| MX2007011151A (es) * | 2005-03-16 | 2007-10-17 | Hoffmann La Roche | Cis-2,4,5-triaril-imidazolinas y su uso como medicamentos anticancer. |
| NZ568285A (en) * | 2005-12-01 | 2011-08-26 | Hoffmann La Roche | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between P53 and MDM2 proteins for use as anticancer agents |
| BRPI0710477A2 (pt) * | 2006-01-18 | 2011-08-16 | Hoffmann La Roche | cis-4, 5- biarila - 2- imidazolinas heterocìclicas como inibidores da mdm2 |
| US7884107B2 (en) | 2006-06-30 | 2011-02-08 | Merck | Substituted piperidines that increase P53 activity and the uses thereof |
| EP2097386A2 (en) * | 2006-11-27 | 2009-09-09 | Novartis AG | Substituted dihydroimidazoles and their use in the treatment of tumors |
| WO2008072655A1 (ja) | 2006-12-14 | 2008-06-19 | Daiichi Sankyo Company, Limited | イミダゾチアゾール誘導体 |
| JP5649825B2 (ja) * | 2007-01-31 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 安定化させたｐ５３ペプチドおよびその使用法 |
| KR101525754B1 (ko) | 2007-03-28 | 2015-06-09 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| CA2701932C (en) | 2007-10-09 | 2015-10-20 | F. Hoffmann-La Roche Ag | Chiral cis-imidazolines |
| JPWO2009151069A1 (ja) | 2008-06-12 | 2011-11-17 | 第一三共株式会社 | ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体 |
| DE102008047128A1 (de) * | 2008-09-15 | 2010-04-15 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Verwendung von cis-Imidazolinen, insbesondere Nutlinen, zur Behandlung von chemoresistenten Krebserkrankungen |
| BRPI1007334A2 (pt) | 2009-01-16 | 2016-02-10 | Daiichi Sankyo Co Ltd | composto, inibidor, medicamento, composição farmacêutica, uso de um composto, agente anticâncer,e , método para tratar câncer. |
| CN104945382B (zh) | 2009-10-14 | 2020-02-07 | 默沙东公司 | 提高p53活性的取代的哌啶和其用途 |
| WO2011060049A2 (en) | 2009-11-12 | 2011-05-19 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| WO2011106650A2 (en) * | 2010-02-27 | 2011-09-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| CN108570097A (zh) | 2010-08-13 | 2018-09-25 | 爱勒让治疗公司 | 拟肽大环化合物 |
| CA2813256A1 (en) | 2010-09-30 | 2012-04-05 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles |
| UA109464C2 (uk) | 2010-11-12 | 2015-08-25 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Спірооксіндольні антагоністи mdm2 |
| EP2684880B1 (en) | 2011-03-10 | 2018-02-28 | Daiichi Sankyo Company, Limited | Dispiropyrrolidine derivative |
| CA2835422C (en) | 2011-05-11 | 2016-10-11 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
| JP6093770B2 (ja) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物 |
| US20140328893A1 (en) | 2011-10-11 | 2014-11-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Nutlin compounds for use in the treatment of pulmonary hypertension |
| MX358886B (es) | 2011-10-18 | 2018-08-31 | Aileron Therapeutics Inc | Macrociclos peptidomimeticos. |
| WO2013062923A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp. | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
| WO2013080141A1 (en) | 2011-11-29 | 2013-06-06 | Novartis Ag | Pyrazolopyrrolidine compounds |
| US9062071B2 (en) | 2011-12-21 | 2015-06-23 | Merck Sharp & Dohme Corp. | Substituted piperidines as HDM2 inhibitors |
| UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| SG11201404648PA (en) | 2012-02-15 | 2014-09-26 | Aileron Therapeutics Inc | Peptidomimetic macrocycles |
| JP6171003B2 (ja) | 2012-05-24 | 2017-07-26 | ノバルティス アーゲー | ピロロピロリジノン化合物 |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| EP2914256B1 (en) | 2012-11-01 | 2019-07-31 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| CA2895504A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
| US9556180B2 (en) | 2013-01-22 | 2017-01-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction |
| WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
| EP2951180B1 (en) * | 2013-01-30 | 2018-05-02 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| EP2961735B1 (en) | 2013-02-28 | 2017-09-27 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| AU2014236812B2 (en) | 2013-03-14 | 2018-03-01 | Amgen Inc. | Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer |
| WO2014165816A1 (en) | 2013-04-05 | 2014-10-09 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
| JP6373978B2 (ja) | 2013-05-27 | 2018-08-15 | ノバルティス アーゲー | イミダゾピロリジノン誘導体および疾患の処置におけるその使用 |
| US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
| AU2014272700B2 (en) | 2013-05-28 | 2016-12-01 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease |
| US9624247B2 (en) | 2013-05-28 | 2017-04-18 | Novartis Ag | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease |
| CN104208066B (zh) * | 2013-06-03 | 2016-06-15 | 中国科学院遗传与发育生物学研究所 | 哌嗪衍生物作为p53分子调节剂的用途 |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| CA2931249A1 (en) | 2013-11-21 | 2015-05-28 | Novartis Ag | Pyrrolopyrrolone derivatives and their use as bet inhibitors |
| CN112972378A (zh) | 2014-09-24 | 2021-06-18 | 艾瑞朗医疗公司 | 拟肽大环化合物及其制剂 |
| JP2017533889A (ja) | 2014-09-24 | 2017-11-16 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその使用 |
| RS58961B1 (sr) | 2015-01-22 | 2019-08-30 | Sanofi Aventis Deutschland | Proces proizvodnje 2-[4-(ciklopropankarbonil)fenil]-2-metil-propannitrila |
| EP3294318A4 (en) | 2015-03-20 | 2019-04-03 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF |
| US10023613B2 (en) | 2015-09-10 | 2018-07-17 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles as modulators of MCL-1 |
| CN113788818A (zh) | 2016-04-06 | 2021-12-14 | 密执安大学评议会 | Mdm2蛋白质降解剂 |
| EP3440082A1 (en) | 2016-04-06 | 2019-02-13 | The Regents of The University of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| JP2019522633A (ja) | 2016-05-20 | 2019-08-15 | ジェネンテック， インコーポレイテッド | Ｐｒｏｔａｃ抗体コンジュゲート及び使用方法 |
| US20210198223A1 (en) * | 2017-10-20 | 2021-07-01 | Corbus Pharmaceuticals, Inc. | Methods and compositions relating to ultrapure 5-(1,1-dimethylheptyl)-resorcinol |
| CN112912143A (zh) | 2018-10-08 | 2021-06-04 | 美国密歇根州立大学试剂中心 | 小分子mdm2蛋白降解剂 |
| TW202200543A (zh) | 2020-03-19 | 2022-01-01 | 美商凱麥拉醫療公司 | Mdm2降解劑及其用途 |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| US11504381B1 (en) * | 2021-11-22 | 2022-11-22 | Ligature Therapeutics Pte. Ltd. | Therapeutic compounds and methods of use thereof |
| US11548866B1 (en) | 2021-11-22 | 2023-01-10 | Ligature Therapeutics Pte. Ltd. | Therapeutic compounds and methods of use thereof |
| KR20230087856A (ko) | 2021-12-10 | 2023-06-19 | 교촌 에프 앤 비(주) | 생체이용율과 이미다졸 펩타이드가 증가된 수용성 닭가슴살 가수분해물 및 그 제조방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02101065A (ja) | 1988-10-06 | 1990-04-12 | Tanabe Seiyaku Co Ltd | イミダゾリン誘導体及びその製法 |
| DE4203547A1 (de) * | 1992-02-07 | 1993-08-12 | Knoll Ag | Verfahren zur racemattrennung von verapamil |
| FR2756560A1 (fr) * | 1996-12-04 | 1998-06-05 | Adir | Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB2351082A (en) | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Synthesis of Cyclic Substituted Amidines |
| US6653501B2 (en) * | 2001-06-27 | 2003-11-25 | Napro Biotherapeutics, Inc. | Chiral resolution method for producing compounds useful in the synthesis of taxanes |
| DE60227108D1 (de) * | 2001-12-18 | 2008-07-24 | Hoffmann La Roche | Cis-imidazoline als mdm2-hemmer |
| ES2301717T3 (es) * | 2001-12-18 | 2008-07-01 | F. Hoffmann-La Roche Ag | Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores. |
-
2005
- 2005-05-10 JP JP2007517027A patent/JP4814228B2/ja not_active Expired - Fee Related
- 2005-05-10 MX MXPA06013246A patent/MXPA06013246A/es active IP Right Grant
- 2005-05-10 EP EP05742255A patent/EP1753727B1/en active Active
- 2005-05-10 ES ES05742255T patent/ES2314660T3/es active Active
- 2005-05-10 DE DE602005011132T patent/DE602005011132D1/de active Active
- 2005-05-10 WO PCT/EP2005/005046 patent/WO2005110996A1/en active Application Filing
- 2005-05-10 KR KR1020087005155A patent/KR20080027969A/ko not_active Application Discontinuation
- 2005-05-10 CN CN200580015663XA patent/CN1953965B/zh not_active Expired - Fee Related
- 2005-05-10 KR KR1020067024089A patent/KR100832277B1/ko not_active IP Right Cessation
- 2005-05-10 AU AU2005243465A patent/AU2005243465B2/en not_active Ceased
- 2005-05-10 AT AT05742255T patent/ATE414693T1/de active
- 2005-05-10 KR KR1020117006619A patent/KR20110033964A/ko not_active IP Right Cessation
- 2005-05-10 RU RU2006144811/04A patent/RU2006144811A/ru not_active Application Discontinuation
- 2005-05-10 CA CA002565189A patent/CA2565189A1/en not_active Abandoned
- 2005-05-10 BR BRPI0511328-8A patent/BRPI0511328A/pt not_active IP Right Cessation
- 2005-05-13 US US11/129,621 patent/US7964724B2/en not_active Expired - Fee Related
- 2005-05-16 MY MYPI20052212A patent/MY143800A/en unknown
- 2005-05-16 PE PE2005000539A patent/PE20060679A1/es not_active Application Discontinuation
- 2005-05-16 TW TW094115741A patent/TW200600501A/zh unknown
- 2005-05-16 AR ARP050101998A patent/AR049545A1/es not_active Application Discontinuation
-
2006
- 2006-10-26 IL IL178884A patent/IL178884A/en not_active IP Right Cessation
- 2006-11-17 ZA ZA200609595A patent/ZA200609595B/xx unknown
- 2006-12-12 NO NO20065730A patent/NO20065730L/no not_active Application Discontinuation
-
2009
- 2009-02-05 US US12/366,381 patent/US20090143364A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL178884A0 (en) | 2007-03-08 |
| TW200600501A (en) | 2006-01-01 |
| US7964724B2 (en) | 2011-06-21 |
| JP4814228B2 (ja) | 2011-11-16 |
| KR20080027969A (ko) | 2008-03-28 |
| CN1953965A (zh) | 2007-04-25 |
| ZA200609595B (en) | 2008-06-25 |
| MY143800A (en) | 2011-07-15 |
| IL178884A (en) | 2010-12-30 |
| ES2314660T3 (es) | 2009-03-16 |
| EP1753727A1 (en) | 2007-02-21 |
| BRPI0511328A (pt) | 2007-12-04 |
| KR100832277B1 (ko) | 2008-05-26 |
| KR20070011516A (ko) | 2007-01-24 |
| KR20110033964A (ko) | 2011-04-01 |
| JP2007538022A (ja) | 2007-12-27 |
| AU2005243465B2 (en) | 2011-08-25 |
| CA2565189A1 (en) | 2005-11-24 |
| AR049545A1 (es) | 2006-08-16 |
| US20090143364A1 (en) | 2009-06-04 |
| EP1753727B1 (en) | 2008-11-19 |
| DE602005011132D1 (de) | 2009-01-02 |
| ATE414693T1 (de) | 2008-12-15 |
| PE20060679A1 (es) | 2006-08-11 |
| AU2005243465A1 (en) | 2005-11-24 |
| RU2006144811A (ru) | 2008-06-27 |
| US20050288287A1 (en) | 2005-12-29 |
| MXPA06013246A (es) | 2007-02-08 |
| CN1953965B (zh) | 2012-07-04 |
| WO2005110996A1 (en) | 2005-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20065730L (no) | Nye CIS-Imidazoliner | |
| PE20030895A1 (es) | Cis-imidazolinas | |
| MXPA04005880A (es) | Cis-imidazolinas como inhibidores de la mdm2. | |
| MX2009011019A (es) | Difenil-dihidro-imidazopiridinonas. | |
| ECSP066753A (es) | Antagonistas del receptor de quimiocina | |
| GT200000002AA (es) | Ureas difenilicias x-carboxiaril sustituidas como inhibidores de raf quinasa | |
| TR200100432T2 (tr) | Hepatit C inhibitörü tri-peptidler | |
| CY1111225T1 (el) | Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c | |
| UY28722A1 (es) | Peptidos macrociclicos activos contra el virus del a hepatitis c | |
| RS52169B (en) | STABLE LAKVINIMOD PREPARATIONS | |
| ECSP055726A (es) | Composición farmacéutica estabilizada que contiene excipientes básicos | |
| NO20062198L (no) | Bradykinin B1 reseptorantagonister | |
| DOP2006000234A (es) | Inhibidores de cinasa | |
| CY1112173T1 (el) | Η χρηση της cilobradine ή των φαρμακευτικα αποδεκτων αλατων αυτης για την θεραπεια ή την προληψη της καρδιακης ανεπαρκειας | |
| ATE477805T1 (de) | 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl- y-aminopropyl-azalide mit antimalaria-aktivität | |
| DK1814848T3 (da) | 2,3,4-substitueret-cyclopentanoner som terapeutiske midler | |
| CY1108599T1 (el) | Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος | |
| ATE412005T1 (de) | Zyklosporinanalog | |
| DE60208180D1 (de) | Modifiziertes, als medikamentvorstufe anwendbares cyclosporin und dessen verwendung | |
| ATE465729T1 (de) | Cis-imidazoline als mdm2-hemmer | |
| TW200510387A (en) | Cis-2, 4, 5-triaryl-imidazolines | |
| EE05241B1 (et) | Distamtsiini a-halogenoakrlolderivaadi kasutamine | |
| DE602006013953D1 (de) | 9a-carbamoyl-y-aminopropyl- und 9a-thiocarbamoyl-y-aminopropyl-azalide mit antimalaria-aktivität | |
| UY27741A1 (es) | Supositorios de meloxicam | |
| NO20045442L (no) | Cykliske peptidiske antibiotika |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |